Oncology Corporate Profile
Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead clinical compound, AR-67 is a novel, third-generation camptothecin analogue that inhibits Topoisomerase I activity.
Website: http://www.arnothera.com/
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| onapristone | anti-progestin | Prostate cancer | II | |
| onapristone | anti-progestin | Various cancer types | I | |
| AR-42 | Pan-DAC/AKT pathway inhibitor | Various cancer types | I | |
| AR-12 | PI3-k/AKT pathway inhibitor | Various cancer types | I |
View additional information on product candidates here »
6/2/2016 05:03 pm
(UCCC/Colorado Cancer Blogs) June 2, 2016 - Paul Bunn, Jr., MD, FASCO, distinguished professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine has been named the 2016 David A. Karnofsky Memorial Award and Lecture recipient, a prestigious award presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting.
3/21/2016 04:33 pm
(OTC Markets) Mar 21, 2016 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in the second stage of its Phase I/II clinical trial evaluating onapristone in men with advanced castration-resistant prostate cancer (CRPC), after failure of abiraterone or enzalutamide.
2/4/2016 12:02 pm
(Wall Street Journal/MoneyBeat blog) Feb 3, 2016 - Highly anticipated results from a phase 3 clinical trial of Keytruda as a single therapy in a form of lung cancer will be available in the middle of the year.
8/18/2015 05:16 pm
(TheStreet) Aug 18, 2015 - Arno Therapeutics, Inc. today announced that it has received authorization from the Medicines and Healthcare products Regulatory Authority (MHRA) to begin enrolling patients in the United Kingdom in the second stage of its Phase I/II clinical trial evaluating lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC).
6/1/2015 06:00 pm
(TheStreet) June 1, 2015 - Clovis and AstraZeneca are developing competing therapies against lung and ovarian cancer.
5/14/2015 06:24 pm
(TheStreet) May 13, 2015 - Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data supporting the ongoing clinical development program for lead compound onapristone to be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.
12/10/2014 08:42 pm
(Yahoo! Finance) Dec 10, 2014 - Study in APR positive endometrioid cancer patients.
9/10/2014 07:05 am
(Medscape Medical News) Sept 10, 2014 - An FDA advisory panel has recommended by a six-to-four vote that a dual-agent medication combining a beta-blocker and an angiotensin-receptor blocker (ARB) not be approved for the treatment of hypertension.
7/21/2014 06:00 am
(Yale Cancer Center) July 17, 2014 – Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers.
5/15/2014 07:20 pm
(NASDAQ) May 14, 2014 - Arno Therapeutics, Inc. today announced two, separate abstracts outlining the study designs of ongoing Phase I clinical trials evaluating its investigational lead compound onapristone to be presented at ASCO.
5/15/2014 09:02 am
(NASDAQ) May 14, 2014 - Arno Therapeutics, Inc. today announced two, separate abstracts outlining the study designs of ongoing Phase I clinical trials evaluating its investigational lead compound onapristone to be presented at ASCO.
4/7/2014 07:32 pm
(Arno Therapeutics) Apr 7, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I/II trial (NCT02049190) evaluating its lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide.
4/7/2014 05:47 pm
(Arno Therapeutics) Apr 7, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I/II trial (NCT02049190) evaluating its lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide.
4/7/2014 02:03 pm
(Arno Therapeutics) Apr 7, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I/II trial (NCT02049190) evaluating its lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide.
1/21/2014 06:17 pm
(MarketWatch) Jan 21, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I dose escalation study evaluating onapristone in post-menopausal women with progesterone receptor (PR) positive tumors, including breast, endometrial and other solid tumors.
1/21/2014 12:01 pm
(MarketWatch) Jan 21, 2014 - Arno Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase I dose escalation study evaluating onapristone in post-menopausal women with progesterone receptor (PR) positive tumors, including breast, endometrial and other solid tumors.
10/15/2013 11:05 am
(Bloomberg) Oct 15, 2013 - Quest Diagnostics Inc., the biggest U.S. operator of medical labs, will sell a test for two breast cancer genes starting today, providing competition for Myriad Genetics Inc. and potentially helping to reduce costs for women fearful they are at risk of the disease.
9/13/2013 11:02 am
(Tribune-Review [Pittsburgh, PA]) Sep 13, 2013 - The feud between Highmark and UPMC has spilled over to Westmoreland County's Arnold Palmer Cancer Pavilion — a joint UPMC-Excela Health venture — where officials say Highmark is refusing to pay reimbursements for chemotherapy treatments.
3/7/2013 12:01 pm
(ASCO in Action) Mar 6, 2013 - ASCO and the American Academy of Hospice and Palliative Care Medicine (AAHPM) today announced a joint initiative to support delivery of high-quality palliative care in medical oncology.
1/16/2013 12:03 pm
(Wall Street Journal) Jan 15, 2013 - Bristol-Myers is scheduled to hold talks to settle hundreds of millions of dollars in claims of liver-disease patients killed or injured during a company-sponsored drug trial last year.
10/19/2012 12:04 pm
(The Business Journal) Oct 18, 2012 - GE Healthcare is launching an initiative to connect people in the fight against breast cancer through the power of music and social media.
6/5/2012 04:02 pm
(Reuters) June 5, 2012 - U.S. drugs regulators rejected an experimental sarcoma medicine from Merck and Ariad Pharmaceuticals on Tuesday, asking for more clinical trials, Merck said.
